Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.

7 , 8 In PRIMED, primary prophylaxis with loperamide resulted in a numerical reduction in the incidence of diarrhea of any grade and ≥ grade 2–34% and 16%, respectively, during the first two cycles, although this improvement did not reach statistical significance.

also in 111,027 other papers